Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS)

Kim, Ji Eun; Choi, Jaesung; Park, Joo Yong; Park, Chulbum; Lee, Se Mi; Park, Seong Eun; Song, Nan; Chung, Shin Hye; Sung, Hyuna; Han, Wonshik; Lee, Jong Won; Park, Sung Sup; Kim, Mi Kyung; Noh, Dong Young; Yoo, Keun Young; Kang, Daehee; Choi, Ji Yeob

doi:10.1038/s41397-018-0016-6

Cited by 12 publications

(10 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the human SLC12A8 gene has been identified as a psoriasis susceptibility candidate gene 33 . Most recently, it has been reported that the high expression of SLC12A8 and its genetic polymorphism are associated with better prognosis of patients with pancreatic ductal adenocarcinomas 34 and breast cancers 35 , respectively. Thus, the Slc12a8 NMN transporter could be a new, interesting target for pharmaceutical drug development.…”

Section: Discussionmentioning

confidence: 99%

Slc12a8 is a nicotinamide mononucleotide transporter

et al. 2019

View full text Add to dashboard Cite

Nicotinamide mononucleotide (NMN) is a biosynthetic precursor of NAD + known to promote cellular NAD + production and counteract age-associated pathologies associated with a decline in tissue NAD + levels. How NMN is taken up into cells has not been entirely clear. Here we show that the Slc12a8 gene encodes a specific NMN transporter. We find that Slc12a8 is highly expressed and regulated by NAD + in the murine small intestine. Slc12a8 knockdown abrogates the uptake of NMN in vitro and in vivo . We further show that Slc12a8 specifically transports NMN, but not nicotinamide riboside, and that NMN transport depends on the presence of sodium ion. Slc12a8 deficiency significantly decreases NAD + levels in the jejunum and ileum, which is associated with reduced NMN uptake as traced by doubly labeled isotopic NMN. Finally, we observe that Slc12a8 expression is upregulated in the aged murine ileum, which contributes to the maintenance of ileal NAD + levels. Our work identifies the first NMN transporter and demonstrates that Slc12a8 has a critical role in regulating intestinal NAD + metabolism.

show abstract

Section: Discussionmentioning

confidence: 99%

Slc12a8 is a nicotinamide mononucleotide transporter

et al. 2019

View full text Add to dashboard Cite

show abstract

“…SLC12A8 is thought to be a candidate for psoriasis susceptibility [26]. Kim et al found that SLC12A8 was correlated with a shorter overall survival of breast cancer patients, probably because the variation of SLC12A8 may be involved in the transportation of chemotherapeutic drugs, leading to a worse prognosis [19]. However, the expression of SLC12A8 in bladder cancer and its mechanism of action have not been reported.…”

Section: Discussionmentioning

confidence: 99%

“…However, the study on SLC12A8 remains limited up to now. On the basis of current researches, we found that the upregulation of SLC12A8 was related to psoriasis, psoriatic arthritis, atopic dermatitis, and breast cancer [17][18][19]. But to our knowledge, no report has been published about the biological function and the regulation of SLC12A8 expression in bladder cancer.…”

Section: Introductionmentioning

confidence: 97%

SLC12A8 plays a key role in bladder cancer progression and EMT

Cao

et al. 2020

Open Medicine

View full text Add to dashboard Cite

Bladder cancer is the most common malignant tumor of the urinary system. The intention of the present research is to explore the prognostic value and biological function of solute carrier family 12 member 8 (SLC12A8) in bladder cancer. The analysis based on the TCGA and ONCOMINE database revealed that the expression of SLC12A8 in bladder cancer was notably increased compared with the normal group. SLC12A8 expression was notably correlated with the age, pathological stage, T-stage, and lymph node metastasis of bladder cancer patients. Moreover, the patients’ overall survival was notably shorter in the high SLC12A8 group. Compared with the control, SLC12A8 upregulation enhanced the proliferative, invasive, and migratory capacities of bladder cancer cells and promoted the expression of epithelial–mesenchymal transition (EMT) protein markers including β-catenin, vimentin, snail, and slug, while reduced the expression of E-cadherin. In the case of downregulated SLC12A8 expression, the proliferative, invasive, and migratory capacities of bladder cancer cells and the expression of EMT protein markers presented the opposite trend. This study demonstrated that SLC12A8 was highly correlated with oncogenesis and progression of bladder cancer, indicating that SLC12A8 may be a meaningful biomarker for initial diagnosis and early treatment of bladder cancer.

show abstract

“…Therefore, ABCB1 polymorphisms do exert significant effects on breast cancer chemotherapy responses. 44 The meta-analysis results conducted by Kim et al 45 polymorphism ABCB1 in rs1045642 (C>T) was associated with poor progressionfree survival (PFS), especially in Asian patients (Hazard Ratio (HR) = 1.56, 95%, Confidence Interval (CI): 1.07-2.27). The association of rs1045642 with PFS was significant in observational studies (HR = 1.28, 95% CI: 1.05-1.56); however, this association was not significant in clinical trials (HR = 1.47, 95% CI: 0.96-2.27).…”

Section: Articles Identified Throughmentioning

confidence: 99%

Genetic Influences in Breast Cancer Drug Resistance

Daniyal

Santoso

Gunawan

et al. 2021

BCTT

View full text Add to dashboard Cite

Breast cancer is the most common cancer in adult women aged 20 to 50 years. The therapeutic regimens that are commonly recommended to treat breast cancer are human epidermal growth factor receptor 2 (HER2) targeted therapy, endocrine therapy, and systemic chemotherapy. The selection of pharmacotherapy is based on the characteristics of the tumor and its hormone receptor status, specifically, the presence of HER2, progesterone receptors, and estrogen receptors. Breast cancer pharmacotherapy often gives different results in various populations, which may cause therapeutic failure. Different types of congenital drug resistance in individuals can cause this. Genetic polymorphism is a factor in the occurrence of congenital drug resistance. This review explores the relationship between genetic polymorphisms and resistance to breast cancer therapy. It considers studies published from 2010 to 2020 concerning the relationship of genetic polymorphisms and breast cancer therapy. Several gene polymorphisms are found to be related to longer overall survival, worse relapse-free survival, higher pathological complete response, and increased diseasefree survival in breast cancer patients. The presence of these gene polymorphisms can be considered in the treatment of breast cancer in order to shape personalized therapy to yield better results.

show abstract

Associations between genetic polymorphisms of membrane transporter genes and prognosis after chemotherapy: meta-analysis and finding from Seoul Breast Cancer Study (SEBCS)

Cited by 12 publications

References 64 publications

Slc12a8 is a nicotinamide mononucleotide transporter

Slc12a8 is a nicotinamide mononucleotide transporter

SLC12A8 plays a key role in bladder cancer progression and EMT

Genetic Influences in Breast Cancer Drug Resistance

Contact Info

Product

Resources

About